Pasotuxizumab  (Synonyms: BAY 2010112; AMG 212; MT112)

Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)^[1][2].

(scFv-heavy-kappa)-(scFv-heavy-lambda)

Human

CD3E & FOLH1

Pasotuxizumab (0-100 ng/mL approximately, 48 h) leads to activation of CD4+ and CD8+ T cell populations, with EC₅₀s of 3.4-6.7 ng/mL for human cocultures, and 13.7-21.2 ng/mL for cynomolgus monkey cell cocultures^[2].
Pasotuxizumab (0-100 ng/mL approximately, 48 h) increases release of interferon-γ, TNF-α, IL-2 and IL-10 in T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pasotuxizumab (0-100 ng/mL approximately, 48 h) leads to activation of CD4+ and CD8+ T cell populations, with EC₅₀s of 3.4-6.7 ng/mL for human cocultures, and 13.7-21.2 ng/mL for cynomolgus monkey cell cocultures^[2].
Pasotuxizumab (0-100 ng/mL approximately, 48 h) increases release of interferon-γ, TNF-α, IL-2 and IL-10 in T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

916  [NCBI] & 2346  [NCBI]

P07766 & Q04609

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

53.55 kDa

1442657-12-6

Liquid

Colorless to light yellow

[Pasotuxizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  (scFv-heavy-kappa)-(scFv-heavy-lambda)

• 
  Immobilized PSMA Protein, Human (HEK293, His, HY-P70548A) can bind Pasotuxizumab. The EC₅₀ for this effect is 315.4 ng/mL.
• 
  Immobilized CD3D-CD3E Heterodimer Protein, Human (HEK293, His, HY-P72726) can bind Pasotuxizumab. The EC₅₀ for this effect is 6.564 ng/mL.

• [1]. Horst-Dieter Hummel, et al. Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2019 37:15_suppl, 5034-5034.

  [2]. Friedrich M, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther. 2012 Dec;11(12):2664-73.  [Content Brief]